澳新食品标准局就L-氨基酸酯用于特医食品征求意见

据澳新食品标准局（FSANZ）消息，8月21日澳新食品标准局发布[22-17]号通报，应新西兰初级产业部的请求，将就L-氨基酸酯（L-amino acid acetate）用于特殊医学用途食品征求意见。有关人员可于2017年8月28日之前提交意见。

在此之前，《澳新食品标准法典》2.9.5号标准附件29-20已批准L-赖氨酸醋酸酯用于特医食品（L-赖氨酸醋酸酯为L-氨基酸酯的一种）。风险评估结论认为，L-氨基酸酯用于特医食品无健康风险。新西兰初级产业部提出本次请求，旨在保障人体健康，并消除对贸易的不良影响。

部分原文报道如下：

FSANZ is considering an urgent Proposal prepared to remove a negative effect on trade in food for special medical purposes and has prepared a draft food regulatory measure. Pursuant to section 96 of the Food Standards Australia New Zealand Act 1991 （FSANZ Act）， FSANZ now calls for submissions to assist its consideration of that draft food regulatory measure.

The Proposal has been declared an urgent Proposal for the purposes of Division 4 of Part 3 of the Food Standards Australia New Zealand Act 1991 （Cth） （the FSANZ Act）.

Standard 2.9.5 and Schedule 29-20 of the Code currently permit L-lysine acetate as the only acetate form of single L-amino acids for use in FSMP.